These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23314910)

  • 41. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    Thromb Haemost; 2015 Jan; 113(1):37-52. PubMed ID: 25231675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
    Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
    J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential statin-clopidogrel interaction requires more study.
    Williams D; Ford I; Hawksworth G
    Circulation; 2004 Aug; 110(6):e68; author reply e68. PubMed ID: 15302814
    [No Abstract]   [Full Text] [Related]  

  • 44. Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
    Laine M; Camoin-Jau L; Bessereau J; Sébastien A; Paganelli F; Bonello L
    Curr Pharm Des; 2012; 18(33):5392-401. PubMed ID: 22724420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinically relevant interaction between clopidogrel and proton pump inhibitors].
    Alban S; Dingermann T; Griese N; Kämmerer W; Schubert-Zsilavecz M; Schulz M; Trenk D; Zagermann-Muncke P
    Pharm Unserer Zeit; 2009; 38(4):370-1. PubMed ID: 19572357
    [No Abstract]   [Full Text] [Related]  

  • 47. Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.
    Karaźniewicz-Łada M; Krzyżańska D; Danielak D; Rzeźniczak J; Główka F; Słomczyński M; Burchardt P
    Eur J Clin Pharmacol; 2020 Mar; 76(3):419-430. PubMed ID: 31897532
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
    Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
    Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proton pump inhibitor and clopidogrel interaction: fact or fiction?
    Laine L; Hennekens C
    Am J Gastroenterol; 2010 Jan; 105(1):34-41. PubMed ID: 19904241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review.
    Kwok CS; Loke YK
    Drug Saf; 2012 Feb; 35(2):127-39. PubMed ID: 22204719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations.
    Tantry US; Kereiakes DJ; Gurbel PA
    JACC Cardiovasc Interv; 2011 Apr; 4(4):365-80. PubMed ID: 21511216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1895-900. PubMed ID: 16645157
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
    J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Safety and effectiveness of combining clopidogrel and proton pump inhibitors].
    Calderón Hernanz B; Pinteño Blanco M; Puigventos Latorre F; Martínez-López I
    Farm Hosp; 2009; 33(6):338-9. PubMed ID: 20038395
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clopidogrel and proton pump inhibitors--boon or bane?].
    Labenz J; Meyners W; Petersen KU
    Dtsch Med Wochenschr; 2010 Feb; 135(5):203-6. PubMed ID: 20104441
    [No Abstract]   [Full Text] [Related]  

  • 58. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coadministration of clopidogrel and proton pump inhibitors.
    Keller DL
    Cleve Clin J Med; 2011 May; 78(5):284; author reply 284-5. PubMed ID: 21688684
    [No Abstract]   [Full Text] [Related]  

  • 60. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
    Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.